Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage

Journal of Hepatology

Volumn 50, Issue 5, 2009, Pages 958-968

  Liu, Chun Jen ^a   Lee, Po Huang ^a   Lin, Deng Yn ^b   Wu, Cheng Chung ^c   Jeng, Long Bin ^d   Lin, Pin Wen ^e   Mok, King Tong ^f   Lee, Wei Chen ^b   Yeh, Hong Zen ^c   Ho, Ming Chih ^a   Yang, Sheng Shun ^c   Lee, Ching Chih ^d   Yu, Ming Chin ^b   Hu, Rey Heng ^a   Peng, Cheng Yuan ^d   Lai, Kuan Lang ^g   Chang, Stanley Shi Chung ^g   Chen, Pei Jer ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^f KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^g Medigen Biotechnology Corporation   (Taiwan)

Author keywords

Efficacy; Hepatocellular carcinoma; Recurrence; Resection; Safety

Indexed keywords

PI 88; PLACEBO;

ACUTE PANCREATITIS; ADJUVANT THERAPY; ADULT; ADVERSE OUTCOME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN HEMORRHAGE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GINGIVA BLEEDING; HUMAN; HUMAN CELL; HUMAN TISSUE; INJECTION SITE BLEEDING; LIVER CELL CARCINOMA; LIVER RUPTURE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PT PROLONGATION; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 84984569951     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.12.023     Document Type: Article

References (33)

1. Rougier P., Mitry E., Barbare J., and Taieb J. Hepatocellular carcinoma (HCC): an update. Semin Oncol 34 (2007) S12-S20
2. Takayama T., Makuuchi M., Hirohashi S., Sakamoto M., Yamamoto J., Shimada K., et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 28 (1998) 1241-1246
3. Nagasue N., Uchida M., Makino Y., Takemoto Y., Yamanoi A., Hayashi T., et al. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 105 (1993) 488-494
4. Belghiti J., Panis Y., Farges O., Benhamou J.P., and Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 214 (1991) 114-117
5. Lai E.C., Fan S.T., Lo C.M., Chu K.M., Liu C.L., and Wong J. Hepatic resection for hepatocellular carcinoma: an audit of 343 patients. Ann Surg 221 (1995) 291-298
6. Funaki N.O., Tanaka J., Seto S., Kasamatsu T., Kaido T., and Imamura M. Hematogenous spreading of hepatocellular carcinoma cells: possible participation in recurrence in the liver. Hepatology 25 (1997) 564-568
7. Chen Y.J., Yeh S.H., Chen J.T., Wu C.C., Hsu M.T., Tsai S.F., et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 119 (2000) 431-440
8. Shirabe K., Kanematsu T., Matsumata T., Adachi E., Akazawa K., and Sugimachi K. Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analysis. Hepatology 14 (1991) 802-805
9. Mathurin P., Raynard B., Dharancy S., Kirzin S., Fallik D., Pruvot F.R., et al. Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Aliment Pharmacol Ther 17 (2003) 1247-1261
10. Muto Y., Moriwaki H., and Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 340 (1999) 1046-1047
11. Ishii H., Yamamoto J., and Ikari T. Adjuvant treatments for resectable hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 15 (2008) 459-462
12. Ikeda K., Arase Y., Saitoh S., Kobayashi M., Suzuki Y., Suzuki F., et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - a prospective randomized study of hepatitis C virus related liver cancer. Hepatology 32 (2000) 228-232
13. Shiratori Y., Shiina S., Teratani T., Imamura M., Obi S., Sato S., et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 138 (2003) 299-306
14. Mazzaferro V., Romito R., Schiavo M., Mariani L., Camerini T., Bhoori S., et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 44 (2006) 1543-1554
15. Lo C.M., Liu C.L., Chan S.C., Lam C.M., Poon R.T., Ng I.O., et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 245 (2007) 831-842
16. Takayama T., Sekine T., Makuuchi M., Yamasaki S., Kosuge T., Yamamoto J., et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomized trial. Lancet 356 (2000) 802-807
17. Kuang M., Peng B.G., Lu M.D., Liang L.J., Huang J.F., He Q., et al. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res 10 (2004) 1574-1579
18. Lau W.Y., Leung T.W., Ho S.K., Chan M., Machin D., Lau J., et al. Adjuvant intra-arterial iodine 131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 353 (1999) 797-801
19. McKenzie E.A. Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol 151 (2007) 1-14
20. Miao H.Q., Liu H., Navarro E., Kussie P., and Zhu Z. Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem 13 (2006) 2101-2111
21. Joyce J.A., Freeman C., Meyer-Morse N., Parish C.R., and Hahahan D. A functional heparan sulphate mimetic implicates both heparanase and heparan sulphate in tumor angiogenesis in a mouse model of multistage cancer. Oncogene 24 (2005) 4037-4051
22. Parish C.R., Freeman C., Brown K.J., Francis D.J., and Cowden W.B. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 59 (1999) 3433-3441
23. Cochran S., Li C., and Fairweather J.K. Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance. J Med Chem 46 (2003) 4601-4608
24. Basche M., Gustafson D.L., Holden S.N., O'Bryant C.L., Gore L., Witta S., et al. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res 12 (2006) 5471-5480
25. Lewis K.D., Robinson W.A., Millward M.J., Powell A., Price T.J., Thomson D.B., et al. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs 26 (2008) 89-94
26. Thall P.F., Simon R., and Ellenberg S.S. Two-stage selection and testing designs for comparative clinical trials. Biometrika 75 (1988) 303-310
27. Bruix J., and Sherman M. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
28. Ishizawa T., Hasegawa K., Aoki T., Takahashi M., Inoue Y., Sano K., et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 134 (2008) 1908-1916
29. Poon R.T., Fan S.T., and Wong J. Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. J Am Coll Surg 194 (2002) 592-602
30. Llovet J.M., Di Bisceglie A.M., Bruix J., Kramer B.S., Lencioni R., Zhu A.X., et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100 (2008) 698-711
31. Huang Y.H., Wu J.C., Lui W.Y., Chau G.Y., Tsay S.H., Chiang J.H., et al. Prospective case-controlled trial of adjuvant chemotherapy after resection of hepatocellular carcinoma. World J Surg 24 (2000) 551-555
32. Lai E.C., Ng I.O., Ng M.M., Lok A.S., Tam P.C., Fan S.T., et al. Long-term results of resection for large hepatocellular carcinoma: a multivariate analysis of clinicopathological features. Hepatology 11 (1990) 815-818
33. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390